

Pavel Sacha

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/573842/publications.pdf>

Version: 2024-02-01

45
papers

1,136
citations

430874

18
h-index

414414

32
g-index

49
all docs

49
docs citations

49
times ranked

1508
citing authors

#	ARTICLE	IF	CITATIONS
1	Structure-activity relationship and biochemical evaluation of novel fibroblast activation protein and prolyl endopeptidase inhibitors with \pm -ketoamide warheads. <i>European Journal of Medicinal Chemistry</i> , 2021, 224, 113717.	5.5	6
2	The role of the biotin linker in polymer antibody mimetics, iBodies, in biochemical assays. <i>Polymer Chemistry</i> , 2021, 12, 6009-6021.	3.9	3
3	The development of a high-affinity conformation-sensitive antibody mimetic using a biocompatible copolymer carrier (iBody). <i>Journal of Biological Chemistry</i> , 2021, 297, 101342.	3.4	2
4	The efficiency of insulin production and its content in insulin-expressing model β -cells correlate with their Zn ²⁺ levels. <i>Open Biology</i> , 2020, 10, 200137.	3.6	5
5	Identification of Novel Carbonic Anhydrase IX Inhibitors Using High-Throughput Screening of Pooled Compound Libraries by DNA-Linked Inhibitor Antibody Assay (DIANA). <i>SLAS Discovery</i> , 2020, 25, 1026-1037.	2.7	2
6	Increasing the throughput of crystallization condition screens: Challenges and pitfalls of acoustic dispensing systems. <i>MethodsX</i> , 2019, 6, 2230-2236.	1.6	4
7	A New Approach for the Diagnosis of Myelodysplastic Syndrome Subtypes Based on Protein Interaction Analysis. <i>Scientific Reports</i> , 2019, 9, 12647.	3.3	8
8	MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition. <i>PLoS Biology</i> , 2019, 17, e3000354.	5.6	94
9	An iBody-based lateral flow assay for semi-quantitative determination of His-tagged protein concentration. <i>Journal of Immunological Methods</i> , 2019, 473, 112640.	1.4	2
10	Inhibitor-Polymer Conjugates as a Versatile Tool for Detection and Visualization of Cancer-Associated Carbonic Anhydrase Isoforms. <i>ACS Omega</i> , 2019, 4, 6746-6756.	3.5	10
11	Tris-(Nitrilotriacetic Acid)-Decorated Polymer Conjugates as Tools for Immobilization and Visualization of His-Tagged Proteins. <i>Catalysts</i> , 2019, 9, 1011.	3.5	6
12	A novel PSMA/GCPII-deficient mouse model shows enlarged seminal vesicles upon aging. <i>Prostate</i> , 2019, 79, 126-139.	2.3	3
13	Inhibitor-GCPII Interaction: Selective and Robust System for Targeting Cancer Cells with Structurally Diverse Nanoparticles. <i>Molecular Pharmaceutics</i> , 2018, 15, 2932-2945.	4.6	25
14	Label-free determination of prostate specific membrane antigen in human whole blood at nanomolar levels by magnetically assisted surface enhanced Raman spectroscopy. <i>Analytica Chimica Acta</i> , 2018, 997, 44-51.	5.4	18
15	DNA-linked inhibitor antibody assay (DIANA) as a new method for screening influenza neuraminidase inhibitors. <i>Biochemical Journal</i> , 2018, 475, 3847-3860.	3.7	5
16	Identification of Protein Targets of Bioactive Small Molecules Using Randomly Photomodified Probes. <i>ACS Chemical Biology</i> , 2018, 13, 3333-3342.	3.4	9
17	DNA-linked Inhibitor Antibody Assay (DIANA) for sensitive and selective enzyme detection and inhibitor screening. <i>Nucleic Acids Research</i> , 2017, 45, e10-e10.	14.5	11
18	Inhibitor-Decorated Polymer Conjugates Targeting Fibroblast Activation Protein. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 8385-8393.	6.4	21

#	ARTICLE	IF	CITATIONS
19	Mouse glutamate carboxypeptidase II (GCPII) has a similar enzyme activity and inhibition profile but a different tissue distribution to human GCPII. FEBS Open Bio, 2017, 7, 1362-1378.	2.3	15
20	Human DNA-Damage-Inducible 2 Protein Is Structurally and Functionally Distinct from Its Yeast Ortholog. Scientific Reports, 2016, 6, 30443.	3.3	46
21	iBodies: Modular Synthetic Antibody Mimetics Based on Hydrophilic Polymers Decorated with Functional Moieties. Angewandte Chemie, 2016, 128, 2402-2406.	2.0	0
22	iBodies: Modular Synthetic Antibody Mimetics Based on Hydrophilic Polymers Decorated with Functional Moieties. Angewandte Chemie - International Edition, 2016, 55, 2356-2360.	13.8	31
23	The Potential Prognostic Markers for Myelodysplastic Syndromes Studied By Surface Plasmon Resonance Imaging and Mass Spectrometry. Blood, 2016, 128, 5510-5510.	1.4	1
24	Measurable Amount of Active Thrombin Is Bound to Circulating D-Dimers. Is There Any Impact on Diagnosis and Pathophysiology of Thrombosis?. Blood, 2016, 128, 2570-2570.	1.4	0
25	The 70-KDa Heat Shock Protein Surface Plasmon Resonance Biosensor for Examination of Blood Plasma Proteome in Myelodysplastic Syndromes Subgroups. Blood, 2016, 128, 5521-5521.	1.4	0
26	Structural and Biochemical Characterization of a Novel Aminopeptidase from Human Intestine. Journal of Biological Chemistry, 2015, 290, 11321-11336.	3.4	14
27	Triggering HIV polyprotein processing by light using rapid photodegradation of a tight-binding protease inhibitor. Nature Communications, 2015, 6, 6461.	12.8	25
28	Design of Highly Potent Urea-Based, Exosite-Binding Inhibitors Selective for Glutamate Carboxypeptidase II. Journal of Medicinal Chemistry, 2015, 58, 4357-4363.	6.4	29
29	Protein Carbonylation in Patients with Myelodysplastic Syndromes. Blood, 2015, 126, 5232-5232.	1.4	1
30	Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA). Prostate, 2014, 74, 1674-1690.	2.3	35
31	Fluorescent Nanodiamonds Embedded in Biocompatible Translucent Shells. Small, 2014, 10, 1106-1115.	10.0	88
32	Detection and quantitation of glutamate carboxypeptidase II in human blood. Prostate, 2014, 74, 768-780.	2.3	14
33	Structural and biochemical characterization of the folylâ€³â€³-glutamate hydrolyzing activity of human glutamate carboxypeptidase II. FEBS Journal, 2014, 281, 3228-3242.	4.7	22
34	Rational design of urea-based glutamate carboxypeptidase II (GCPII) inhibitors as versatile tools for specific drug targeting and delivery. Bioorganic and Medicinal Chemistry, 2014, 22, 4099-4108.	3.0	37
35	Glutamate carboxypeptidase II does not process amyloidâ€² peptide. FASEB Journal, 2013, 27, 2626-2632.	0.5	4
36	GCPII Variants, Paralogs and Orthologs. Current Medicinal Chemistry, 2012, 19, 1316-1322.	2.4	13

#	ARTICLE	IF	CITATIONS
37	Efficient and versatile one-step affinity purification of in vivo biotinylated proteins: Expression, characterization and structure analysis of recombinant human glutamate carboxypeptidase II. <i>Protein Expression and Purification</i> , 2012, 82, 106-115.	1.3	38
38	The antifungal effect of peptides from hymenoptera venom and their analogs. <i>Open Life Sciences</i> , 2011, 6, 150-159.	1.4	10
39	Prostate-specific membrane antigen and its truncated form PSM ² . <i>Prostate</i> , 2009, 69, 471-479.	2.3	19
40	Tissue expression and enzymologic characterization of human prostate specific membrane antigen and its rat and pig orthologs. <i>Prostate</i> , 2008, 68, 171-182.	2.3	42
41	Expression of glutamate carboxypeptidase II in human brain. <i>Neuroscience</i> , 2007, 144, 1361-1372.	2.3	116
42	Biochemical characterization of human glutamate carboxypeptidase III. <i>Journal of Neurochemistry</i> , 2006, 101, 682-696.	3.9	51
43	Amino acids at the N- and C-termini of human glutamate carboxypeptidase II are required for enzymatic activity and proper folding. <i>FEBS Journal</i> , 2004, 271, 2782-2790.	0.2	29
44	Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. <i>Protein Science</i> , 2004, 13, 1627-1635.	7.6	93
45	Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II. <i>Journal of Neurochemistry</i> , 2002, 80, 477-487.	3.9	113